Pfizer sank -5.1% this evening, compared to the S&P 500's day change of 1.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:
-
Pfizer has logged a -43.0% 52 week change, compared to 14.0% for the S&P 500
-
PFE has an average analyst rating of buy and is -27.91% away from its mean target price of $40.1 per share
-
Its trailing earnings per share (EPS) is $1.83, which brings its trailing Price to Earnings (P/E) ratio to 15.8. The Health Care sector's average P/E ratio is 30.21
-
The company's forward earnings per share (EPS) is $3.15 and its forward P/E ratio is 9.2
-
The company has a Price to Book (P/B) ratio of 1.68 in contrast to the Health Care sector's average P/B ratio is 4.08
-
The company's free cash flow for the last fiscal year was $18.87 Billion and the average free cash flow growth rate is 5.3%
-
Pfizer's revenues have an average growth rate of 9.0% with operating expenses growing at None%. The company's current operating margins stand at 15.2%